PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Fluorescent Endothelin GO Peptides - AnaSpec is pleased to announce the release of new HiLyte Fluor™ 488 and 5-FAM labeled Endothelin peptides (human, bovine, porcine, rat) adding on its Endothelin peptides collection
AnaSpec Introduces Fluorescent Endothelin GO Peptides


NewswireToday - /newswire/ - Fremont, CA, United States, 2010/10/21 - AnaSpec is pleased to announce the release of new HiLyte Fluor™ 488 and 5-FAM labeled Endothelin peptides (human, bovine, porcine, rat) adding on its Endothelin peptides collection.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Endothelins (ET) are highly potent vasoconstrictor proteins distributed throughout all areas of the body, and are implicated in a number of conditions and diseases.1 Members of the Endothelin family of peptides consist of Pre-pro-endothelin-1, a biologically inactive precursor form cleaved by furin covertase to produce Big Endothelin-1 (Big ET-1), which is cleaved again by endothelin converting enzyme (ECE) between Trp-21 and Val-22 to yield the active ET-1 (1-21).2 Alternatively, pulmonary chymase is also capable of generating ET-1 (1-31) by cleaving the Tyr31–Gly32 bond of big ET-1.2, 3 Isoforms include ET-2, ET-3, and ET-4.2 All have two disulfide bonds that hold them in a conical spiral shape.2 In addition to their vasoconstrictive properties, endothelins have inotropic and mitogenic properties.2 They influence salt and water balance, affect intracellular Ca2+ concentrations and signal transduction cascades, contract non-vascular smooth muscle, alter central and peripheral sympathetic activity, and stimulate the renin-angiotensin-aldosterone system.2-5

ETs are normally kept at stable levels in healthy individuals, but can become overexpressed, leading to high blood pressure, kidney disease, and numerous cardiovascular diseases such as pulmonary hypertension, cardiac hypertrophy, myocardial infarction, heart failure, and cerebral vasospasm.1, 2 ET disregulation is also a key component of tumorigenesis in several types of cancer.6

Fluorescently labeled endothelins have various applications in ET-related disease research. They are utilized as probes in visualizing intracellular processes and molecular interactions between ET-1 and potential ET-antagonists or inhibitors at the cellular level.7 They are also used for localizing and monitoring ECE activity and ET-receptor binding affinity via fluorescence fluctuation spectroscopy.8, 9 Specific ET isoform binding sites throughout the body may be studied using labeled ET. In addition, flow cytometry is used in combination with labeled ET to assay ET-receptor expression during different periods of the cell cycle,10 and in vivo and in vitro imaging of ET activity is capable with fluorescent ET.11 Overall, these unique peptides offer a wide range of approaches to further studying ET function and ET-related mechanisms.

1. Palma, BD. et al. Brazilian J. Med. Biol. Res. 35, 75 (2002).
2. Lüscher, T. Circulation 102, 2434 (2000).
3. Fecteau, M. et al. Hypertension 46, 87 (2005).
4. Inoue, A. et al. J. Biol. Chem. 264, 14954 (1989).
5. Highsmith, RF. et al. FASEB J. 9, 1196 (1995).
6. Smith, K. et al. Br. J. Cancer 88, 163 (2003).
7. Boese, G. et al. J. Cardiovasc. Pharmacol. 36, S44 (2000).
8. Heilker, R. et al. Biochem. 43, 9021 (2004).
9. Higuchi, K. et al. J. Biol. Chem. 266, 18352 (1991).
10. Kobayashi, S. et al. J. Biol. Chem. 273, 12584 (1998).
11. Clark, JC. et al. Br. J. Pharmacol. 159, 812 (2010).

About AnaSpec
AnaSpec ( is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

About Eurogentec
Eurogentec ( is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: AnaSpec, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

AnaSpec Introduces Fluorescent Endothelin GO Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Tiffany Kao - 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From AnaSpec, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (